Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 1,07,237.41 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Mankind Pharma Limited was incorporated on July 3 1991 as a Private Limited Company with the name Mankind Pharma Private Limited by the Registrar of Companies Delhi and Haryana at New Delhi. Pursuant ...

Mankind Pharma, operating in the Pharmaceuticals sector and classified as a Largecap on the BSE, currently has its share price at ₹2582.65. The stock has experienced fluctuations today ...

Mankind Pharma has officially completed the amalgamation of three of its subsidiaries—Shree Jee Laboratory Private Limited, JPR Labs Private Limited, and Jaspack Industries Private Limited—into the ...

New Delhi: Mankind Pharma has announced that the Board of Directors of the Company at its meeting has inter-alia, considered and approved the constitution of a ‘Structural Integration Committee’ to ...

Mankind Pharma announces plans to integrate Bharat Serums & Vaccines (BSV). A committee will evaluate structures for integration, with a decision expected in coming months. New Delhi, Apr 14 (PTI) ...

The Quarterly Results page of Mankind Pharma Ltd. presents the key result items, its comparison with the sector peers and its previous 5 Quarterly Results.

Mankind Pharma plans to integrate Bharat Serums and Vaccines (BSV) by forming a committee to evaluate structural alternatives. A detailed plan will be presented to the board after consulting advisors.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Return on investment - most recent fiscal year 22.45 ...

Mankind Pharma has entered into a partnership with Innovent Biologics for exclusively licensing and commercialising Sintilimab, an immunotherapy for cancer treatment in India. This strategic move ...